Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010 | Zendy

Lauri E. Markowitz | Zendy; Susan Hariri | Zendy; Carol Y. Lin | Zendy; Eileen F. Dunne | Zendy; Martin Steinau | Zendy; Geraldine M. McQuillan | Zendy; Elizabeth R. Unger | Zendy

Open Access

Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010

Author(s) -

Lauri E. Markowitz,

Susan Hariri,

Carol Y. Lin,

Eileen F. Dunne,

Martin Steinau,

Geraldine M. McQuillan,

Elizabeth R. Unger

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit192

Subject(s) - medicine , vaccination , confidence interval , national health and nutrition examination survey , human papillomavirus , hpv vaccines , immunization , demography , hpv infection , gynecology , cervical cancer , population , immunology , environmental health , cancer , antibody , sociology

Human papillomavirus (HPV) vaccination was introduced into the routine immunization schedule in the United States in late 2006 for females aged 11 or 12 years, with catch-up vaccination recommended for those aged 13-26 years. In 2010, 3-dose vaccine coverage was only 32% among 13-17 year-olds. Reduction in the prevalence of HPV types targeted by the quadrivalent vaccine (HPV-6, -11, -16, and -18) will be one of the first measures of vaccine impact.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research